Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay Hoong Chow

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersKay Hoong Chow, Tongrong Wang, Ilke Tunali, et al.
Leukemia & Lymphoma|January 7, 2016
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemiaDavid A Rizzieri, Sarah Cooley, Olatoyosi Odenike, et al.
Investigational New Drugs|September 28, 2014
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumorsRobert M Jotte, Daniel D Von Hoff, Fadi Braiteh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersKay Hoong Chow, Tongrong Wang, Ilke Tunali, et al.
Leukemia & Lymphoma|January 7, 2016
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemiaDavid A Rizzieri, Sarah Cooley, Olatoyosi Odenike, et al.
Investigational New Drugs|September 28, 2014
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumorsRobert M Jotte, Daniel D Von Hoff, Fadi Braiteh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Pageof 1